Healthcare - Biotechnology - NASDAQ - GB
$ 1.79
-5.79 %
$ 7.77 M
Market Cap
-0.53
P/E
CASH FLOW STATEMENT
-6.25 M
OPERATING CASH FLOW
-1.16 M
INVESTING CASH FLOW
1.65 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Virax Biolabs Group Limited
| Net Income | -6.74 M |
| Depreciation & Amortization | 103 K |
| Capital Expenditures | -1.16 M |
| Stock-Based Compensation | 1.01 M |
| Change in Working Capital | -1.12 M |
| Others | 228 K |
| Free Cash Flow | -7.41 M |
Cash Flow
Millions
| Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (6.7) | (5.5) | (1.7) | (0.7) | (0.7) |
| Depreciation & Amortization | 0.1 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 1.0 | 1.7 | 0.3 | 0 | 0 |
| Other Operating Activities | 0.5 | (0.3) | 32.1 K | 1.19 K | 91.7 K |
| Change in Working Capital | (1.1) | (0.2) | 0.6 | 59.6 K | 96.8 K |
| Cash From Operations | (6.2) | (4.2) | (0.8) | (0.6) | (0.7) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (1.2) | (0.2) | 0 | 0 | 0 |
| Other Items | 0 | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | (1.2) | (0.2) | 0 | 0 | 0 |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | (0.2) | 0.1 | 100 K | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.9 | (0.1) | 0.2 | 0.6 | 0.7 |
| Cash From Financing Activities | 1.6 | 13.7 | 0.8 | 0.6 | 0.7 |
| CHANGE IN CASH | |||||
| Net Change In Cash | (5.8) | 9.3 | 4.14 K | 4.99 K | 40 K |
| FREE CASH FLOW | |||||
| Free Cash Flow | (7.4) | (4.4) | (0.8) | (0.6) | (0.7) |